ucart123
cellectis
['ameli-01', 'cellectis']
tomorrow, december 13th, will host a live #webcast to review the company s clinical data on the ameli-01 study (evaluating ucart123) presented at the annual meeting and provide a company update. don't forget to register here: 
Cellectis is gene editing the first of its kind, off-the-shelf UCART immunotherapies to fight blood cancers. Community Guidelines: https://t.co/PpAC8G7hQp